Roche has completed its acquisition of Carmot Therapeutics, a clinical-stage biotechnology company developing therapeutics for metabolic diseases, for $2.7 billion and as much as $400 million based on the achievement of certain milestones. Roche obtains access to Carmot’s current R&D portfolio including all clinical and preclinical assets, as well as exclusive access to Carmot’s Chemotype Evolution discovery platform in metabolism. Carmot and its employees will join the Roche Group as pa...